September 20, 2007 — North American Scientific, Inc. announced that it has completed the sale of its NOMOS Radiation Oncology business to privately-held Best Medical International, Inc.
“We have successfully closed this transaction in a timely manner and we are now positioned to focus on our core brachytherapy growth strategy,” said John Rush, President and Chief Executive Officer of North American Scientific. “With this divestiture complete, we can focus our resources on the commercialization of our ClearPath HDR and ClearPath CR products, which offer innovative therapeutic options to patients suffering from breast cancer, and the continued sales growth of our prostate brachytherapy products. We believe these products will allow us to address an $800 million market opportunity in the U.S. and we are excited to pursue this strategy.”
For more information: www.nasmedical.com
April 20, 2026 
